Personalized brain activity models in Alzheimer’s disease detect synergistic amyloid-β and tau impacts on neuronal excitability values, which significantly predict brain atrophy, p-tau217 plasma concentrations, and cognitive deterioration. This evidence concerns the gene MAPT and Alzheimer disease.